Scientists Crack the Code for Finding Molecular Glue Drugs

A New Era for Drug Discovery

Scientists have developed a groundbreaking method that could transform how we find an entirely new class of medicines called molecular glue drugs. Published in Nature Chemical Biology, the research turns what has historically been a process driven by lucky accidents into a rational, repeatable system.

Molecular glues work differently from traditional drugs. Instead of blocking a protein's function directly, they force disease-causing proteins to interact with the cell's natural waste-disposal system, effectively marking them for destruction. The problem has always been that nearly every molecular glue discovered so far was found by accident, severely limiting the potential of this promising drug class.

How the Method Works

The team, led by Georg Winter of the AITHYRA Research Institute in Vienna and Michael Erb of the Scripps Research Institute in California, starts with a small molecule already known to bind a target protein. They then systematically attach thousands of different molecular building blocks, creating over three thousand chemical variants. Each variant subtly reshapes the protein's surface, potentially enabling new protein-to-protein interactions that trigger degradation.

Using high-throughput chemical synthesis combined with functional cell screening, the researchers can rapidly test which compounds produce the desired biological effect, a scale of exploration that was previously impractical.

Proof of Concept in Leukemia

To demonstrate their method, the team targeted ENL, a protein central to certain forms of acute leukemia. From their compound library, they identified a molecule called dHTC1 that triggers potent and selective degradation of ENL in leukemia cells. The compound works cooperatively, first binding ENL and then creating a new interaction surface that recruits the cell's protein-disposal machinery.

Why This Matters

Approximately eighty percent of proteins in human cells lack the binding pockets that conventional drugs need to work, rendering them effectively undruggable. Molecular glues offer a way around this limitation by hijacking existing cellular machinery. With a systematic discovery method now in hand, researchers can begin tackling a vast landscape of previously untreatable diseases. Three molecular glue drugs have already been approved for clinical use, with numerous candidates in development and industry investment exceeding thirteen billion dollars in recent deals.